Janssen expects Europe to approve its Covid-19 vaccine in March

The company has already submitted the results of the phase 3 clinical trial to the EMA.

A health worker prepares a vaccine against Covid-19.

Pharmaceutical Janssen foresees that the European Medicines Agency (EMA, for its acronym in English) give your okay to his coronavirus vaccine in March. This is how the CEO of Janssen Italia and president of the Italian pharmaceutical industry, Massimo Scaccabarozzi, advanced in an interview at the Corriere della Sera collected by Europa Press.

“We have presented the phase 3 assay, so the antigen it should be cleared by the EMA in March. It was tested in 43,783 participants of various age groups and in different parts of the world, from the United States to Latin America, passing through South Africa, in the period in which the infection was greatest ”, he explained.

In this context, he pointed out that Janssen’s Covid-19 vaccine yes it could be more effective against the South African variant than others, like that of AstraZeneca. “South African President Cyril Ramaphosa has said that he has high expectations for our vaccine. We tested the vaccine in South Africa at a time when the variant was already in circulation, and the average efficacy in the moderate and severe forms was 66%, ”he highlighted.

Asked if his vaccine prevents contagion and not only serious illness and death, Scaccabarozzi stressed that “there is currently no evidence that vaccines can prevent transmission.” “Longer observation times are needed“, Has pointed out.

The single-dose Janssen antigen leverages the company’s ‘AdVac’ vaccine platform, which was also used to develop and make the Ebola virus vaccine. It is stable in storage at 2-8ºC for three months and at -20ºC for two years.